BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 16447135)

  • 1. Update on vaccine liability in the United States: presentation at the National Vaccine Program Office Workshop on strengthening the supply of routinely recommended vaccines in the United States, 12 February 2002.
    Evans G
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S130-7. PubMed ID: 16447135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Keys to strengthening the supply of routinely recommended vaccines: view from industry.
    Pisano W
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S111-7. PubMed ID: 16447131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The National Vaccine Injury Compensation Program.
    Cook KM; Evans G
    Pediatrics; 2011 May; 127 Suppl 1():S74-7. PubMed ID: 21502255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The United States pediatric vaccine stockpile program.
    Lane KS; Chu SY; Santoli JM
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S125-9. PubMed ID: 16447134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strengthening the supply of routinely recommended vaccines in the United States: a perspective from the American Medical Association.
    Tan L;
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S121-4. PubMed ID: 16447133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationalizing vaccine injury compensation.
    Mello MM
    Bioethics; 2008 Jan; 22(1):32-42. PubMed ID: 18154587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the National Vaccine Injury Compensation Program.
    Edlich RF; Olson DM; Olson BM; Greene JA; Gubler KD; Winters KL; Kelley AR; Britt LD; Long WB
    J Emerg Med; 2007 Aug; 33(2):199-211. PubMed ID: 17692778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, supply, and suits--litigation and the vaccine industry.
    Kesselheim A
    N Engl J Med; 2011 Apr; 364(16):1485-7. PubMed ID: 21506740
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunity for immunizations: tort liability, biodefense, and Bioshield II.
    Mayer L
    Stanford Law Rev; 2007 Apr; 59(6):1753-90. PubMed ID: 17593591
    [No Abstract]   [Full Text] [Related]  

  • 10. National Vaccine Injury Compensation Program (VICP): effective date provisions of coverage of certain vaccines to the vaccine injury table--HRSA. Final rule.
    Fed Regist; 1998 May; 63(90):25777-8. PubMed ID: 10179332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administrative compensation of medical injuries: a hardy perennial blooms again.
    Barringer PJ; Studdert DM; Kachalia AB; Mello MM
    J Health Polit Policy Law; 2008 Aug; 33(4):725-60. PubMed ID: 18617673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician concerns about vaccine adverse effects and potential litigation.
    Zimmerman RK; Schlesselman JJ; Mieczkowski TA; Medsger AR; Raymund M
    Arch Pediatr Adolesc Med; 1998 Jan; 152(1):12-9. PubMed ID: 9452702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creating a sustainable immunization system in Canada--the case for a vaccine-related injury compensation scheme.
    Kutlesa NJ
    Health Law J; 2004; 12():201-42. PubMed ID: 16539082
    [No Abstract]   [Full Text] [Related]  

  • 14. Strengthening the supply of routinely administered vaccines in the United States: problems and proposed solutions.
    Klein JO; Myers MG
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S97-103. PubMed ID: 16447139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No-fault vaccine insurance: lessons from the National Vaccine Injury Compensation Program.
    Ridgway D
    J Health Polit Policy Law; 1999 Feb; 24(1):59-90. PubMed ID: 10342255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Notes and comments "High and dry?" The Public Readiness and Emergency Preparedness Act and liability protection for pharmaceutical manufacturers.
    Copper BK
    J Health Law; 2007; 40(1):65-105. PubMed ID: 17549932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMA offers recommendations for vaccine injury compensation.
    Goldsmith MF
    JAMA; 1984 Dec; 252(21):2937-9, 2942-3. PubMed ID: 6502847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Closing the Door to Lost Earnings Under the National Childhood Vaccine Injury Act of 1986.
    Levin A
    Food Drug Law J; 2015; 70(4):593-616, ii-iii. PubMed ID: 26827393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A response to strategy #2: streamlining the regulatory process.
    Glezen WP
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S141-4. PubMed ID: 16447137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The National Childhood Vaccine Injury Act and the supreme court's interpretation.
    Blake V
    Virtual Mentor; 2012 Jan; 14(1):31-4. PubMed ID: 23116914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.